Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy

Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy

Jinling Jiang,1 Tao Ma,1 Wenqi Xi,1 Chen Yang,1 Junwei Wu,1 Chenfei Zhou,1 Nan Wang,1 Zhenggang Zhu,1,2 Jun Zhang1,2 1Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People’s Republic of China; 2Shanghai Institute of Digestive Sur...

Full description

Bibliographic Details
Main Authors: Jiang J, Ma T, Xi W, Yang C, Wu J, Zhou C, Wang N, Zhu Z, Zhang J
Format: Article
Language:English
Published: Dove Medical Press 2019-09-01
Series:Cancer Management and Research
Subjects:
inflammatory biomarkers
cetuximab
early treatment response
wild-type RAS
metastatic colorectal cancer
Online Access:https://www.dovepress.com/pre-treatment-inflammatory-biomarkers-predict-early-treatment-response-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/pre-treatment-inflammatory-biomarkers-predict-early-treatment-response-peer-reviewed-article-CMAR

Similar Items